{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.82","upperLimit":"-0.37","value":"-2.59"},{"groupId":"OG001","lowerLimit":"-5.52","upperLimit":"-1.01","value":"-3.27"},{"groupId":"OG002","lowerLimit":"-3.77","upperLimit":"-0.76","value":"-2.26"},{"groupId":"OG003","lowerLimit":"-3.89","upperLimit":"-0.46","value":"-2.17"},{"groupId":"OG004","lowerLimit":"-3.60","upperLimit":"0.56","value":"-1.52"},{"groupId":"OG005","lowerLimit":"-4.57","upperLimit":"-0.29","value":"-2.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.57","upperLimit":"-1.12","value":"-3.34"},{"groupId":"OG001","lowerLimit":"-5.43","upperLimit":"-0.93","value":"-3.18"},{"groupId":"OG002","lowerLimit":"-4.55","upperLimit":"-1.51","value":"-3.03"},{"groupId":"OG003","lowerLimit":"-4.85","upperLimit":"-1.35","value":"-3.10"},{"groupId":"OG004","lowerLimit":"-2.61","upperLimit":"1.69","value":"-0.46"},{"groupId":"OG005","lowerLimit":"-3.37","upperLimit":"0.90","value":"-1.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.07","upperLimit":"-1.62","value":"-3.84"},{"groupId":"OG001","lowerLimit":"-6.38","upperLimit":"-1.82","value":"-4.10"},{"groupId":"OG002","lowerLimit":"-4.14","upperLimit":"-1.05","value":"-2.59"},{"groupId":"OG003","lowerLimit":"-3.72","upperLimit":"-0.19","value":"-1.95"},{"groupId":"OG004","lowerLimit":"-3.38","upperLimit":"1.01","value":"-1.19"},{"groupId":"OG005","lowerLimit":"-4.12","upperLimit":"0.24","value":"-1.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.69","upperLimit":"-2.24","value":"-4.47"},{"groupId":"OG001","lowerLimit":"-6.27","upperLimit":"-1.66","value":"-3.96"},{"groupId":"OG002","lowerLimit":"-4.33","upperLimit":"-1.16","value":"-2.75"},{"groupId":"OG003","lowerLimit":"-4.82","upperLimit":"-1.25","value":"-3.03"},{"groupId":"OG004","lowerLimit":"-3.74","upperLimit":"0.72","value":"-1.51"},{"groupId":"OG005","lowerLimit":"-3.46","upperLimit":"0.95","value":"-1.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.73","upperLimit":"-1.28","value":"-3.51"},{"groupId":"OG001","lowerLimit":"-6.56","upperLimit":"-1.94","value":"-4.25"},{"groupId":"OG002","lowerLimit":"-4.90","upperLimit":"-1.72","value":"-3.31"},{"groupId":"OG003","lowerLimit":"-5.61","upperLimit":"-1.98","value":"-3.79"},{"groupId":"OG004","lowerLimit":"-2.64","upperLimit":"1.81","value":"-0.42"},{"groupId":"OG005","lowerLimit":"-2.54","upperLimit":"1.96","value":"-0.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.41","upperLimit":"-1.92","value":"-4.17"},{"groupId":"OG001","lowerLimit":"-7.23","upperLimit":"-2.50","value":"-4.86"},{"groupId":"OG002","lowerLimit":"-3.86","upperLimit":"-0.66","value":"-2.26"},{"groupId":"OG003","lowerLimit":"-5.90","upperLimit":"-2.22","value":"-4.06"},{"groupId":"OG004","lowerLimit":"-3.34","upperLimit":"1.17","value":"-1.09"},{"groupId":"OG005","lowerLimit":"-2.10","upperLimit":"2.45","value":"0.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.38","upperLimit":"-0.80","value":"-3.09"},{"groupId":"OG001","lowerLimit":"-7.28","upperLimit":"-2.55","value":"-4.92"},{"groupId":"OG002","lowerLimit":"-3.54","upperLimit":"-0.34","value":"-1.94"},{"groupId":"OG003","lowerLimit":"-6.14","upperLimit":"-2.39","value":"-4.27"},{"groupId":"OG004","lowerLimit":"-5.29","upperLimit":"-0.66","value":"-2.97"},{"groupId":"OG005","lowerLimit":"-2.60","upperLimit":"2.22","value":"-0.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 10 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.30","upperLimit":"-1.61","value":"-3.95"},{"groupId":"OG001","lowerLimit":"-7.97","upperLimit":"-3.24","value":"-5.60"},{"groupId":"OG002","lowerLimit":"-2.40","upperLimit":"0.95","value":"-0.72"},{"groupId":"OG003","lowerLimit":"-6.83","upperLimit":"-2.77","value":"-4.80"},{"groupId":"OG004","lowerLimit":"-4.29","upperLimit":"0.42","value":"-1.94"},{"groupId":"OG005","lowerLimit":"-3.81","upperLimit":"1.01","value":"-1.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.18","upperLimit":"-1.43","value":"-3.81"},{"groupId":"OG001","lowerLimit":"-8.35","upperLimit":"-3.25","value":"-5.80"},{"groupId":"OG002","lowerLimit":"-4.41","upperLimit":"-0.76","value":"-2.58"},{"groupId":"OG003","lowerLimit":"-6.41","upperLimit":"-2.17","value":"-4.29"},{"groupId":"OG004","lowerLimit":"-4.40","upperLimit":"0.94","value":"-1.73"},{"groupId":"OG005","lowerLimit":"-2.59","upperLimit":"2.42","value":"-0.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 14 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.40","upperLimit":"0.89","value":"-1.75"},{"groupId":"OG001","lowerLimit":"-7.51","upperLimit":"-1.71","value":"-4.61"},{"groupId":"OG002","lowerLimit":"-4.35","upperLimit":"0.06","value":"-2.15"},{"groupId":"OG003","lowerLimit":"-6.90","upperLimit":"-2.41","value":"-4.65"},{"groupId":"OG004","lowerLimit":"-5.50","upperLimit":"1.07","value":"-2.22"},{"groupId":"OG005","lowerLimit":"-2.65","upperLimit":"2.71","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.49","upperLimit":"-1.49","value":"-4.49"},{"groupId":"OG001","lowerLimit":"-10.59","upperLimit":"-3.46","value":"-7.02"},{"groupId":"OG002","lowerLimit":"-4.22","upperLimit":"0.31","value":"-1.96"},{"groupId":"OG003","lowerLimit":"-5.21","upperLimit":"-0.51","value":"-2.86"},{"groupId":"OG004","lowerLimit":"-8.25","upperLimit":"6.03","value":"-1.11"},{"groupId":"OG005","lowerLimit":"-1.66","upperLimit":"5.41","value":"1.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-8.55","upperLimit":"-1.46","value":"-5.01"},{"groupId":"OG001","lowerLimit":"-9.06","upperLimit":"-1.29","value":"-5.17"},{"groupId":"OG002","lowerLimit":"-4.70","upperLimit":"1.06","value":"-1.82"},{"groupId":"OG003","lowerLimit":"-6.31","upperLimit":"-0.95","value":"-3.63"},{"groupId":"OG005","lowerLimit":"-1.66","upperLimit":"5.41","value":"1.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.79","upperLimit":"0.94","value":"-2.93"},{"groupId":"OG001","lowerLimit":"-9.00","upperLimit":"-0.26","value":"-4.63"},{"groupId":"OG002","lowerLimit":"-5.68","upperLimit":"0.96","value":"-2.36"},{"groupId":"OG003","lowerLimit":"-8.87","upperLimit":"-2.12","value":"-5.50"},{"groupId":"OG005","lowerLimit":"-6.73","upperLimit":"1.94","value":"-2.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 22 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-11.66","upperLimit":"-2.96","value":"-7.31"},{"groupId":"OG001","lowerLimit":"-10.00","upperLimit":"-1.26","value":"-5.63"},{"groupId":"OG002","lowerLimit":"-7.04","upperLimit":"1.28","value":"-2.88"},{"groupId":"OG003","lowerLimit":"-8.10","upperLimit":"0.32","value":"-3.89"},{"groupId":"OG005","lowerLimit":"-2.06","upperLimit":"6.61","value":"2.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-10.67","upperLimit":"-0.33","value":"-5.50"},{"groupId":"OG002","lowerLimit":"-10.01","upperLimit":"3.95","value":"-3.03"},{"groupId":"OG003","lowerLimit":"-11.31","upperLimit":"2.70","value":"-4.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"title":"Cycle 26 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-9.23","upperLimit":"-0.32","value":"-4.77"},{"groupId":"OG001","lowerLimit":"-5.61","upperLimit":"4.15","value":"-0.73"},{"groupId":"OG002","lowerLimit":"-5.28","upperLimit":"0.18","value":"-2.55"},{"groupId":"OG003","lowerLimit":"-5.49","upperLimit":"-0.95","value":"-3.22"},{"groupId":"OG004","lowerLimit":"-2.70","upperLimit":"4.17","value":"0.74"},{"groupId":"OG005","lowerLimit":"-5.65","upperLimit":"1.50","value":"-2.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"End of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"description":"The Beck Depression Inventory (BDI)-II is a 21-item self-report scale, with each item rated by participants on a 4-point scale (ranging from 0-3, where 0 indicated lowest depression and 3 indicated severe depression). The scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike, pessimism, and poor concentration) as well as somatic signs (appetite, sleep, fatigue and libido). Scores were obtained by adding up the total points from the series of answers. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Treatment-naïve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG000","title":"EXP-1 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG001","title":"EXP-2 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG002","title":"EXP-3 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG003","title":"EXP-4 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG004","title":"EXP-5 (Phase 2)"},{"description":"Participants with advanced ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG005","title":"EXP-6 (Phase 2)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"PRO evaluable analysis set included all enrolled participants who received study treatment, had a baseline test assessment and at least 1 on-study test assessment. Here, 'Number Analyzed' signifies participants evaluable for specified row.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)","title":"Change From Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2)","type":"SECONDARY","unitOfMeasure":"Units on a scale"}